Overactive Bladder News and Research

RSS

Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia."

Nationwide survey finds only 13% of women have been diagnosed with OAB symptoms

Today, the National Association for Continence (NAFC) announced findings from a new, nationwide survey of women about overactive bladder (OAB).

14 Mar 2013

Mirabegron reduces frequency of incontinence episodes in phase III trial

In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.

5 Mar 2013

FDA accepts Antares Pharma's New Drug Application for OTREXUP

Antares Pharma, Inc. today announced that the New Drug Application for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

27 Feb 2013

Antimuscarinic effective for overactive bladder in elderly

The antimuscarinic drug fesoterodine seems to be an effective and well-tolerated treatment for elderly individuals with an overactive bladder, including those older than 75 years, show findings from a clinical trial.

19 Feb 2013

Targacept reports net loss of $15.9 million for fourth quarter 2012

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

Epithelium able to sense bladder fullness through activity of integrins

If you have an overactive bladder or incontinence, help could be on the way. A new research report published online in the FASEB Journal, shows that the epithelium, a thin layer of cells which line the surface of the bladder, is able to sense how full the bladder is through the action of a family of proteins called integrins.

11 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Merck receives FDA approval for Oxytrol to treat overactive bladder in women

The U.S. Food and Drug Administration today approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older.

28 Jan 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Allergan receives FDA approval for Botox to treat overactive bladder

The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.

18 Jan 2013

Vaginal transobturator tape boosts incontinence cure rates

Implantation of tension-free vaginal transobturator tape is a highly effective and long lasting treatment for women with stress urinary incontinence.

31 Dec 2012

New coverage decisions by private payers and Medicare for OAB and urge incontinence

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by private payers and Medicare.

27 Nov 2012

Adrenoreceptor shows potential in overactive bladder treatment

Mirabegron, a β3-adrenoreceptor agonist, has shown 12-month safety, tolerability, and persistence of effect in patients with overactive bladders, show study findings.

14 Nov 2012

National Association For Continence to host free educational events from Nov. 12 - 16

The National Association For Continence (NAFC) is hosting free educational events during National Bladder Health Week. Bladder Health Week occurs every year during the second full week in November. This year Bladder Health Week will be held from November 12 - 16.

7 Nov 2012

NAFC conducts online survey to examine women’s perceptions about overactive bladder

The National Association For Continence (NAFC) is conducting an anonymous online survey to understand the perceptions women, age 40-65, have about overactive bladder (OAB) and what they are prepared to do about its symptoms. Using constructs from the Health Belief Model, this survey aims to explain the fears and preparedness women have towards general health and OAB. This research is conducted by Kelton Global Research, a market research company and supported by a grant from Merck Pharmaceuticals.

26 Oct 2012

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

The American Urological Association (AUA) introduces new clinical guidelines for the treatment of Overactive Bladder, Urodynamics, Hematuria, and Vasectomy.

24 Oct 2012

Oral medication as effective as Botox injections for treating incontinence in women

Oral medication for treating a type of incontinence in women is roughly as effective as Botox injections to the bladder, reported researchers who conducted a National Institutes of Health clinical trials network study, with each form of treatment having benefits and limitations.

6 Oct 2012

Positive results from Antares Pharma’s VIBEX MTX clinical study on rheumatoid arthritis

Antares Pharma, Inc. today announced positive results from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX).

25 Sep 2012

Antimuscarinics only moderately effective for overactive bladder

A comprehensive review of oral antimuscarinics for the treatment of overactive bladder concludes that the efficacy of treatment is, at best, moderate.

17 Sep 2012

Pfizer, Mylan enter settlement agreement to resolve generic Detrol LA litigation

Mylan Inc. today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

7 Sep 2012